Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

Molecular distinctiveness of duodenal-type follicular lymphoma revealed by integrated multi-omic analysis

Hisashi Hashimoto, Suguru Fukuhara, Akiko Miyagi Maeshima, Mai Takeuchi, Shinichi Makita, Noriko Iwaki, Wataru Munakata, Masayoshi Yamada, Seiichiro Abe, Yutaka Saito, Hiroyuki Mano, Koji Izutsu, Yosuke Tanaka

Blood (2025) 146 (Supplement 1): 3524.

https://doi.org/10.1182/blood-2025-3524

Published: 2025

Journal Articles

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Vincent Ribrag, Yi Lin, Rashmi Bhatnagar, Sandrine Montheard, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2025-3710

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Molecular determinants of therapeutic response to nivolumab in Relapsed/Refractory PTCL: An integrated multiomic study of A phase II investigator-initiated trial

Takeshi Sugio, Soyeong Jun, Hideki Goto, Yoshihiro Kameoka, Go Yamamoto, Jiro Fujita, Toshio Kitawaki, Ritsuro Suzuki, Mari Olsen, Chih Long Liu, Koji Izutsu, Hirohiko Shibayama, Junji Suzumiya, Maximilian Diehn, Koichi Akashi, Ash Alizadeh, Koji Kato

Blood (2025) 146 (Supplement 1): 5414.

https://doi.org/10.1182/blood-2025-5414

Published: 2025

Journal Articles

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Reem Karmali, Franck Morschhauser, Koji Izutsu, Lia Palomba, Kirit Ardeshna, Brian Hill, Manali Kamdar, Stephen J. Schuster, Antonio Pinto, Saurabh Dahiya, Merav Bar, Maria Strocchia, Jinender Kumar, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 709.

https://doi.org/10.1182/blood-2025-709

Published: 2025

Journal Articles

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Blood (2025) 146 (Supplement 1): 467.

https://doi.org/10.1182/blood-2025-467

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Blood (2025) 146 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2025-2115

Published: 2025

Journal Articles

Whole-genome analysis reveals shared early genetic alterations and subtype-specific immune evasion pathways in intravascular large B-cell lymphoma and immune-privileged large B-cell lymphoma

Takuto Mori, Kazuyuki Shimada, Kaito Mimura, Suguru Fukuhara, Koji Izutsu, Daisuke Kawauchi, Yoshitaka Narita, Akiko Miyagi Maeshima, Ryosuke Koyamada, Nobuhiro Hiramoto, Nobuyuki Kakiuchi, Hirona Maeda, Ai Okada, Kenichi Chiba, Yuichi Shiraishi, Akifumi Takaori-Kondo, Seishi Ogawa, Akihiro Tomita, Kenichi Yoshida

Blood (2025) 146 (Supplement 1): 7061.

https://doi.org/10.1182/blood-2025-7061

Published: 2025

Journal Articles

Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy

Risa Nishiyama, Shinichi Makita, Mai Takeuchi, Akiko Miyagi Maeshima, Kimiteru Ito, Wataru Takeda, Shotaro Watanabe, Yuta Ito, Noriko Iwaki, Suguru Fukuhara, Wataru Munakata, Koji Izutsu

Blood (2025) 146 (Supplement 1): 5440.

https://doi.org/10.1182/blood-2025-5440

Published: 2025

Journal Articles

Treatment patterns and outcomes for large B-cell lymphoma patients with central nervous system relapse: A multicenter retrospective study (CoNSensus Study)

Blood (2025) 146 (Supplement 1): 5435.

https://doi.org/10.1182/blood-2025-5435

Published: 2025

Journal Articles

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis

Pier Luigi Zinzani, Neha Mehta-Shah, Jasmine Zain, Giuseppe Gritti, Lauren Pinter-Brown, Koji Izutsu, Ohad S. Bentur, David Sidransky, Jonathan Brammer, Barbara Pro, Christopher Fox, Steven Horwitz

Blood (2025) 146 (Supplement 1): 3634.

https://doi.org/10.1182/blood-2025-3634

Published: 2025

Journal Articles

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies

Toby Eyre, Matthew S Davids, Jeff Sharman, Paul Barr, Catherine Coombs, Wojciech Jurczak, Koji Izutsu, Meghan Thompson, William Wierda, Ying (denise) Wang, Marisa Hill, Donald Tsai, Ching Ching Leow, Sarang Abhyankar, Paolo Ghia, Jennifer Woyach

Blood (2025) 146 (Supplement 1): 5670.

https://doi.org/10.1182/blood-2025-5670

Published: 2025

Journal Articles

Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational Study in Japan

Blood (2025) 146 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2025-1865

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3)

Koji Izutsu, Noriko Fukuhara, Makoto Sugaya, Yuichi Baba, Jin Hayakawa, Mitsufumi Nishio, Alev Akyol, Akshay Sudhindra, Kenji Ishitsuka

Blood (2024) 144 (Supplement 1): 3123.3.

https://doi.org/10.1182/blood-2024-203202

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Clinical Features and Outcomes of Localized Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Dual-Center Retrospective Observational Study with a Long-Term Follow-up

Blood (2024) 144 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2024-193605

Published: 2024

Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood (2024) 144 (Supplement 1): 72.

https://doi.org/10.1182/blood-2024-199813

Published: 2024

Journal Articles

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Blood (2024) 144 (Supplement 1): 868.

https://doi.org/10.1182/blood-2024-193681

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Molecular distinctiveness of duodenal-type follicular lymphoma revealed by integrated multi-omic analysis

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Molecular determinants of therapeutic response to nivolumab in Relapsed/Refractory PTCL: An integrated multiomic study of A phase II investigator-initiated trial

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Whole-genome analysis reveals shared early genetic alterations and subtype-specific immune evasion pathways in intravascular large B-cell lymphoma and immune-privileged large B-cell lymphoma

Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy

Treatment patterns and outcomes for large B-cell lymphoma patients with central nervous system relapse: A multicenter retrospective study (CoNSensus Study)

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies

Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational Study in Japan

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3)

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Clinical Features and Outcomes of Localized Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Dual-Center Retrospective Observational Study with a Long-Term Follow-up

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only